

(FOR REFERENCE PURPOSE)

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail

(Security code: 4552)

June 24, 2020

To the Shareholders

3-19 Kasuga-cho, Ashiya, Hyogo, 659-0021
JCR Pharmaceuticals Co., Ltd.
Representative Director, Chairman and President
Shin Ashida

Notice of Resolutions Passed at The 45th Ordinary General Meeting of Shareholders

Thank you very much for your continued support.

We wish to notify you of the following report and resolutions passed at the 45th Ordinary General Meeting of Shareholders held today.

■ Reporting on the Business Report

Non-Consolidated Financial Statements and Consolidated Financial Statements, and Audit Report of Consolidated Financial Statements by the Accounting Auditor and the Audit & Supervisory Board for the 45th fiscal year (from April 1, 2019 to March 31, 2020)

The Company reported on the above-mentioned content.

■Resolution Matters

Proposal 1

Appointment of nine (9) members to the Board of Directors

As per the original proposal, the following seven (7) people have each been reelected and appointed to the Board of Directors: Shin Ashida, Hiroshi Yoshimoto, Toru Ashida, Toshihiro Ishikiriyama, Takashi Suetsuna, Toshihide Yoda, and Yuko Hayashi. In addition, as per the original proposal, the following two (2) people have each been newly elected and appointed to the Board of Directors: Hiroyuki Sonoda and Mathias Schmidt.

Proposal 2

Issuance of share options to directors, presidents of overseas subsidiaries, and corporate officers for stock option scheme as a stock-linked compensation plan

The matter received approval as per the original proposal.

■Regarding Payment of Term-End Dividends

Term-end dividends for the 45th fiscal year will be paid as follows:

- (1) For those who have designated payment by bank account transfer, we ask that you please confirm the “Dividend Statement” and “Transfer Destination” documents enclosed. For those who have designated allocation in proportion to the number of shares, please confirm the “Dividend Statement” and “Method for Receiving the Dividend” documents enclosed.
- (2) For those who have not designated payment by bank account transfer, we ask that you pick up the term-end dividend payment at the nearest Japan Post Bank using the “Year-End Dividend Receipt” document enclosed.